dalteparin has been researched along with Cancer of Pelvis in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Enoxaparin, 40 mg once daily, is as safe and effective as unfractionated heparin three times daily in preventing venous thromboembolism in patients undergoing major elective surgery for abdominal or pelvic malignancy." | 2.68 | Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. ( , 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcipérez de Vargas, FJ | 1 |
| Marcos, G | 1 |
| Moyano Calvente, SL | 1 |
| Sakon, M | 1 |
| Kobayashi, T | 1 |
| Shimazui, T | 1 |
| Bergqvist, D | 1 |
| Agnelli, G | 1 |
| Cohen, AT | 1 |
| Eldor, A | 1 |
| Nilsson, PE | 1 |
| Le Moigne-Amrani, A | 1 |
| Dietrich-Neto, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873] | Phase 2 | 35 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.) | ||
| Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.[NCT02597218] | 350 participants (Anticipated) | Observational | 2015-10-31 | Recruiting | |||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for dalteparin and Cancer of Pelvis
| Article | Year |
|---|---|
Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study.
Topics: Abdominal Neoplasms; Aged; Anticoagulants; Asian People; Drug Administration Schedule; Enoxaparin; F | 2010 |
Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Double-Bl | 1997 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
1 other study available for dalteparin and Cancer of Pelvis
| Article | Year |
|---|---|
Pulmonary embolism as a first manifestation of intracardiac extension of an endometrial stromal sarcoma.
Topics: Anticoagulants; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Endometrial Neoplasms; E | 2014 |